Study details
Enrolling now
Vancomycin Study for Multiple Sclerosis (MS)
Icahn School of Medicine at Mount Sinai
NCT IDNCT05539729ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
12
Study length
about 3.7 years
Ages
18–50
Locations
1 site in NY
About this study
This trial is testing whether vancomycin affects the gut microbiome and immune function in people with multiple sclerosis. The goal is to understand how vancomycin might influence the connection between the gut and brain in MS.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Vancomycin
PhasePhase 1
DrugVancomycin
Routeinfusion
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
vancomycin
Drug routes
infusion
Body systems
Neurology